Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript)Seeking Alpha • 01/09/24
Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance WoesInvestors Business Daily • 01/08/24
Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple CountriesPRNewsWire • 01/08/24
Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024GlobeNewsWire • 01/05/24
Earnings Estimates Moving Higher for Regeneron (REGN): Time to Buy?Zacks Investment Research • 01/03/24
Regeneron (REGN) Surges 3.0%: Is This an Indication of Further Gains?Zacks Investment Research • 01/03/24
Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/18/23
Regeneron Pharmaceuticals Inc. (REGN) American Society of Hematology 2023 Investor Conference - (Transcript)Seeking Alpha • 12/14/23
Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive YearGlobeNewsWire • 12/11/23
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported OutcomesGlobeNewsWire • 12/11/23
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term OutcomesGlobeNewsWire • 12/10/23